Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

Paolo F. Caimi, Scott F Huntington, Sean Landrette, Sheryl M Gough, Vivian Dai, Bryan Jackson, Tinghui Yu, Juan Chavez, Sarah Tannenbaum-Dvir, Matthew Matasar

Blood (2024) 144 (Supplement 1): 6505.

https://doi.org/10.1182/blood-2024-208356

Published: 2024

Journal Articles

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Kunal C Potnis, Satoko Ito, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, Jan Philipp Bewersdorf, George Goshua

Blood (2024) 144 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2024-204312

Published: 2024

Journal Articles

Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients

Haris Qureshi, Ahmad Kiwan, Francine M. Foss, Shalin Kothari, Scott F Huntington, Iris Isufi, Stuart Seropian, Tarsheen Sethi

Blood (2024) 144 (Supplement 1): 6421.

https://doi.org/10.1182/blood-2024-211850

Published: 2024

Journal Articles

Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

Blood (2024) 144 (Supplement 1): 387.

https://doi.org/10.1182/blood-2024-194607

Published: 2024

Journal Articles

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Abdulrahman Alhajahjeh, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf

Blood (2024) 144 (Supplement 1): 788.

https://doi.org/10.1182/blood-2024-201535

Published: 2024

Journal Articles

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Adam J. Olszewski, Matthew Matasar, Scott F Huntington, Thomas Ollila, Ari Pelcovits, Yun Kyoung Tiger, John L. Reagan, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Charles Milrod, Patrycja M. Dubielecka

Blood (2024) 144 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2024-193022

Published: 2024

Journal Articles

Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Jalpa A. Doshi, Pengxiang Li, Zhi Geng, Xiudong Lei, Amy Pettit, Katrina A. Armstrong, Scott F Huntington, John K Lin

Blood (2024) 144 (Supplement 1): 786.

https://doi.org/10.1182/blood-2024-203410

Published: 2024

Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch

Blood (2024) 144 (Supplement 1): 782.

https://doi.org/10.1182/blood-2024-198414

Published: 2024

Journal Articles

Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Charles Milrod, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Christina Raker, Thomas Ollila, Seo-Ho Lee, Ari Pelcovits, John L. Reagan, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Matthew Matasar, Scott F Huntington, Patrycja M. Dubielecka, Adam J. Olszewski

Blood (2024) 144 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2024-193023

Published: 2024

Journal Articles

Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy

Amer M. Zeidan, Yanqing Xu, Tatyana A. Kapustyan, Kaylee Miu, Cheng Chen, Rajesh Kamalakar, Chia-Wei Lin, Esprit Ma, Melissa Montez, Zheng Wu, Tracy Yee, Haiyan Sun, Andrew Rava, Sonia Kim, Scott F Huntington

Blood (2024) 144 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2024-200213

Published: 2024

Journal Articles

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Patrick Squires, Justin T. Puckett, Katherine Elizabeth Ryland, Sachin Kamal-Bahl, Monika Raut, Jalpa A. Doshi, Scott F. Huntington

Blood (2023) 142 (Supplement 1): 2326.

https://doi.org/10.1182/blood-2023-181024

Published: 2023

Journal Articles

Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims

Scott F. Huntington, Hsien-Yen Chang, Alex Z. Fu, Christina Loefgren, Xiaoxiao Lu

Blood (2023) 142 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2023-181909

Published: 2023

Journal Articles

Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data

Scott F. Huntington, Hsien-Yen Chang, Alex Z. Fu, Christina Loefgren, Xiaoxiao Lu

Blood (2023) 142 (Supplement 1): 2428.

https://doi.org/10.1182/blood-2023-178755

Published: 2023

Journal Articles

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Adam J Olszewski, Thomas Ollila, Ari Pelcovits, Anna Dorota Chorzalska, John Morgan, Jessica McMahon, Stephen Donnelly, Scott F. Huntington, Matthew Matasar, John L. Reagan, Charles Milrod, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2023-181418

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

Beenish S Manzoor, Scott F. Huntington, Dureshahwar Jawaid, Justin T. Puckett, Nnadozie Emechebe, Arliene Ravelo, Sachin Kamal-Bahl, Jalpa A. Doshi

Blood (2023) 142 (Supplement 1): 5085.

https://doi.org/10.1182/blood-2023-177939

Published: 2023

Journal Articles

Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study

Enrico De Nigris, Wendy Y. Cheng, Eric M. Sarpong, Siyang Leng, Mohammed Z.H. Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh, Scott F. Huntington

Blood (2023) 142 (Supplement 1): 6523.

https://doi.org/10.1182/blood-2023-178660

Published: 2023

Journal Articles

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev

Blood (2022) 140 (Supplement 1): 11004–11006.

https://doi.org/10.1182/blood-2022-165156

Published: 2022

Journal Articles

Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia

Amer M. Zeidan, Wei-Han Cheng, Rajesh Kamalakar, Catherine Miller, Cat N. Bui, Melissa Montez, Tracy Yee, Zheng Wu, Scott F. Huntington

Blood (2022) 140 (Supplement 1): 3282–3283.

https://doi.org/10.1182/blood-2022-160002

Published: 2022

Journal Articles

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Mengyang Di, Jessica B Long, Iris Isufi, Francine M. Foss, Stuart Seropian, Cary P Gross, Scott F. Huntington

Blood (2022) 140 (Supplement 1): 10818–10819.

https://doi.org/10.1182/blood-2022-164915

Published: 2022

NARROW

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients

Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims

Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only